PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Journal of Advanced Research1 citationsOpen Access

Asprosin-driven metabolic-epigenetic rewiring attenuates mesenchymal stem cell senescence with therapeutic benefits for infarcted hearts

View Full Paper
ZZZhengbin ZhangZWZiqian WangLZLiwen Zhu

Key Points

  • Asprosin rejuvenates mesenchymal stem cells, counteracting senescence effectively.
  • This metabolic-epigenetic interplay showcases the potential for regenerative therapies targeting heart diseases.
  • The study emphasizes the 'Glycolysis-Lactylation-Epigenetics' axis as a transformative strategy in treatment.
  • Findings indicate that enhancing asprosin pathways may lead to significant therapeutic advancements.

Abstract

Asprosin is a novel MSC-specific rejuvenation factor that antagonizes senescence through metabolic-epigenetic interplay. Targeting the asprosin-driven "Glycolysis-Lactylation-Epigenetics" axis offers a transformative strategy to enhance MSC-based therapies for ischemic heart disease.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/69a75eb3c6e9836116a298fehttps://doi.org/10.1016/j.jare.2026.01.073
Ask AI
Helpful
Bookmark
Share
View Full Paper